Sigilon Therapeutics
Ulrik B. Nielsen, Ph.D., is co-founder and CEO of Tidal Therapeutics, a company developing nucleotide-based therapeutics He was previously a co-founder, President and CEO of Torque Therapeutics from 2015 until 2018. Prior to Torque, Dr. Nielsen was co-founder and Chief Scientific Officer of Merrimack (NASDAQ: MACK) until 2015. Dr. Nielsen also serves on the Board of Directors for Alloy, Merrimack and North Therapeutics. He trained at the University of California, San Francisco, and MIT, and holds a Ph.D. in molecular biology from the University of Copenhagen.
This person is not in the org chart
This person is not in any offices
Sigilon Therapeutics
2 followers
Sigilon Therapeutics’ mission is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases.